Cerebral Spasticity News

FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen (Baclofen Injection) for the Treatment of Severe Spasticity

Posted 23 Nov 2010 by Drugs.com

ST. PAUL, Minn.--(BUSINESS WIRE)--Nov 23, 2010 - Today, CNS Therapeutics announced the FDA approval of Gablofen (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a new, easy-to-administer and cost-effective intrathecal baclofen treatment option. Severe spasticity is a movement disorder affecting more than 500,000 patients in the U.S. alone and is often brought on by multiple sclerosis, cerebral palsy, spinal cord injury, brain trauma and stroke. Richard Penn, M.D., a pioneer in intrathecal drug therapies and CNS Therapeutics co-founder and chief scientific officer, implanted the industry's first programmable intrathecal drug pump more than 25 years ago. "Until now, the evolution of intrathecal therapies has been limited to modest innovations in implantable devices," said Penn. "With Gablofen, CNS Therapeutics is driving the industry ahead ... Read more

Related support groups: Baclofen, Chronic Spasticity, Cerebral Spasticity